This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| Rolls-Royce Holdings | 1,278.0 | 11.9% |
| Easyjet | 392.9 | 10.0% |
| Antofagasta | 3,777.0 | 8.8% |
| Spirax Group | 7,242.0 | 8.5% |
| Standard Chartered | 1,725.0 | 8.2% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| BP | 562.7 | -5.8% |
| Shell | 3,401.0 | -4.7% |
| Centrica | 213.4 | -2.4% |
| British American Tobacco | 4,424.0 | -0.3% |
| Admiral Group | 3,223.0 | -0.3% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 10,609 | 2.5% | 38.2% |
| DOW JONES INDUS. AVG | 47,910 | 2.9% | 18.0% |
| DAX INDEX | 24,081 | 5.1% | 22.4% |
| NIKKEI 225 | 55,953 | -0.6% | 76.1% |
| S&P/ASX 200 INDEX | 8,973 | 0.2% | 21.7% |
| Commodity | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 97.68 | 3.46% |
| Brent Crude (ICE) | USD/bbl. | 97.05 | 2.43% |
| Gold Spot | USD/t oz. | 4,717 | 0.04% |
| Copper (Comex) | USd/lb. | 572 | -0.96% |
Click graph to enlarge
The UK 100 is called to open +50 points at at 10,659. The UK 100 is poised to open higher on Thursday, tracking oil prices above $97/barrel as the Strait of Hormuz remains blocked despite the US-Iran ceasefire. Following a 2.5% surge yesterday to 10,608.88, the index is forecast to gain over 50 points. While US stocks rallied strongly overnight (Dow +2.9%, Nasdaq +2.8%), Asian markets have dipped slightly (Nikkei -0.6%, Shanghai -0.7%) as optimism fades.
Banking giant HSBC has recently been in the spotlight as it continues to navigate a complex landscape of economic uncertainty and interest rate hikes. Analysts are watching closely to see how the bank’s international operations, particularly in Asia, will perform in the face of slower global growth. Investors are also keen to see how HSBC responds to increasing regulatory scrutiny, especially with the Bank of England’s recent signals about tightening regulations for large financial institutions.
Leading UK pharmaceutical firm AstraZeneca, continues to shine as its portfolio of oncology drugs and recent successes in immunotherapy make it one of the more resilient performers in the UK 100. The company is expected to see continued revenue growth as it advances several drugs through late-stage trials. The focus has been on their cancer treatment pipeline, which could add significant value to their long-term growth potential. Some analysts are also speculating about further acquisitions to expand its reach in the biopharmaceutical space.
UK
Metlen Energy & Metals (MTLN) – Full Year Results
US
None
UK
Unite Group (UTG) – Trading update and Q1 fund valuations
US
None
US Personal Consumption Expenditures – Price Index
US Gross Domestic Product
US Initial Jobless Claims
US Personal Income
US Personal Spending
UK 100 companies going ex-dividend on 9th April 2026:
Standard Life
Lloyds Banking Group
Reckitt Benckiser Group
Croda International
Howden Joinery Group
Centrica
Haleon
Rentokil Initial
InterContinental Hotels Group
UK 250 companies going ex-dividend on 9th April 2026:
ITV
TP ICAP Group
Man Group
Morgan Advanced Minerals
Savills
Harbour Energy
Serco Group
Hunting
Softcat
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.